These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32112304)

  • 1. Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.
    Newman B; Witzmann K
    Pharmaceut Med; 2020 Apr; 34(2):93-102. PubMed ID: 32112304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for the Forced Expiratory Volume in 1 Second-Based Comparative Clinical Endpoint Bioequivalence Studies for Orally Inhaled Drug Products.
    Lee J; Feng K; Conti DS; Walenga R; Wientjes M; Wang H; Newman B; Han L; Dhapare S; Bielski E; Babiskin A; Wu F; Donnelly M; Kim MJ; Jiang W; Luke MC; Fang L; Zhao L
    Clin Pharmacol Ther; 2022 Nov; 112(5):982-989. PubMed ID: 35133652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.
    Lee SL; Saluja B; García-Arieta A; Santos GM; Li Y; Lu S; Hou S; Rebello J; Vaidya A; Gogtay J; Purandare S; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1285-304. PubMed ID: 26002510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Silico Methods for Development of Generic Drug-Device Combination Orally Inhaled Drug Products.
    Walenga RL; Babiskin AH; Zhao L
    CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):359-370. PubMed ID: 31044532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research and Education Needs for Complex Generics.
    Stern S; Coghlan J; Krishnan V; Raney SG; Babiskin A; Jiang W; Lionberger R; Xu X; Schwendeman A; Polli JE
    Pharm Res; 2021 Dec; 38(12):1991-2001. PubMed ID: 34950975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Bioequivalence between Generic and Originator Orally Inhaled Drug Products: Validity of Administration of Doses above the Approved Single Maximum Dose.
    Singh GJP; Hickey AJ
    Mol Pharm; 2024 Sep; 21(9):4191-4198. PubMed ID: 39133824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
    Choi SH; Lionberger RA
    AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.
    Hochhaus G; Davis-Cutting C; Oliver M; Lee SL; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1305-11. PubMed ID: 26033698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the safety of generic drugs.
    Dighe SV
    Transplant Proc; 1999 May; 31(3A Suppl):23S-24S. PubMed ID: 10330955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways.
    Klein K; Borchard G; Shah VP; Flühmann B; McNeil SE; de Vlieger JSB
    Ann N Y Acad Sci; 2021 Oct; 1502(1):5-13. PubMed ID: 34296458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
    Lu D; Lee SL; Lionberger RA; Choi S; Adams W; Caramenico HN; Chowdhury BA; Conner DP; Katial R; Limb S; Peters JR; Yu L; Seymour S; Li BV
    AAPS J; 2015 May; 17(3):546-57. PubMed ID: 25758352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Essentialities in Establishing the Bioequivalence of Oral Inhalation Drug Products to be Marketed in the USA.
    Fernandes SD; Koland M
    Ther Innov Regul Sci; 2020 Jul; 54(4):738-748. PubMed ID: 32557296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of regulations for bioequivalence assessment of locally acting orally inhaled drug products for the United States, Europe, Canada, and India.
    Patil PP; Pawar AP; Mahadik KR; Gaikwad VL
    Expert Opin Drug Deliv; 2021 Dec; 18(12):1843-1855. PubMed ID: 34814778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.
    Liu Q; Absar M; Saluja B; Guo C; Chowdhury B; Lionberger R; Conner DP; Li BV
    AAPS J; 2019 Jan; 21(2):14. PubMed ID: 30617594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic drug device combination products: Regulatory and scientific considerations.
    Choi SH; Wang Y; Conti DS; Raney SG; Delvadia R; Leboeuf AA; Witzmann K
    Int J Pharm; 2018 Jun; 544(2):443-454. PubMed ID: 29170118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Product selection, bioequivalence, and therapeutic equivalence: the generic drug market.
    Halperin JA
    Drug Inf J; 1983; 17(2):73-6. PubMed ID: 10263719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of distinctions and parallels between the US and EU guidelines for determination of comparative effectiveness and safety of the orally inhaled drug products.
    Singh GJP
    Eur J Pharm Sci; 2024 Oct; 201():106872. PubMed ID: 39117248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA's Generic Drug Program: Decreasing Time to Approval and Number of Review Cycles.
    Chazin H; Woo J; Han J; Grosser S; Luan J
    Ther Innov Regul Sci; 2020 Jul; 54(4):758-763. PubMed ID: 32557293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.